Exelixis (EXEL) News Today → RE: Your account status (From MarketBeat) (Ad) Free EXEL Stock Alerts $20.34 -0.23 (-1.12%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 4:05 PM | businesswire.comExelixis to Present at the William Blair 44th Annual Growth Stock ConferenceMay 28 at 2:08 AM | americanbankingnews.comBrokerages Set Exelixis, Inc. (NASDAQ:EXEL) PT at $26.13May 27 at 5:52 AM | marketbeat.com3,061,647 Shares in Exelixis, Inc. (NASDAQ:EXEL) Purchased by Norges BankNorges Bank acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 3,061,647 shares of the biotechnology company's stock, valued at approximately $73,449,000. Norges Bank owned appMay 26 at 12:48 AM | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Stock Position Lowered by Amalgamated BankAmalgamated Bank decreased its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 27.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 168,482 shares of the biotechnology company's stock after sellMay 25 at 4:45 AM | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of "Moderate Buy" by BrokeragesExelixis, Inc. (NASDAQ:EXEL - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seventeen research firms that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating and ten have given a buy rating to the cMay 24, 2024 | benzinga.comDirector At Exelixis Sells $576K Of StockMay 24, 2024 | marketbeat.comPanagora Asset Management Inc. Sells 37,636 Shares of Exelixis, Inc. (NASDAQ:EXEL)Panagora Asset Management Inc. decreased its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 50.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,530 shares of the biotechnology company's sMay 24, 2024 | americanbankingnews.comGeorge Poste Sells 11,686 Shares of Exelixis, Inc. (NASDAQ:EXEL) StockMay 24, 2024 | finance.yahoo.comDirector Julie Smith Sells 27,280 Shares of Exelixis Inc (EXEL)May 23, 2024 | insidertrades.comExelixis, Inc. (NASDAQ:EXEL) Director George Poste Sells 11,686 SharesMay 22, 2024 | marketbeat.comTrexquant Investment LP Has $5.26 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)Trexquant Investment LP trimmed its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 51.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 219,347 shares of theMay 21, 2024 | markets.businessinsider.comBuy Rating for Exelixis: Navigating Patent Lifecycles and Bolstering Growth with a Robust PipelineMay 20, 2024 | markets.businessinsider.comExelixis Resolves Two CABOMETYX Patent Disputes With CiplaMay 20, 2024 | businesswire.comExelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USAMay 20, 2024 | marketbeat.comJump Financial LLC Sells 127,788 Shares of Exelixis, Inc. (NASDAQ:EXEL)Jump Financial LLC trimmed its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 79.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,210 shares of the biotechnology company's stock after sellinMay 18, 2024 | americanbankingnews.comExelixis, Inc. (NASDAQ:EXEL) Director Sells $233,424.51 in StockMay 17, 2024 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Short Interest Up 11.0% in AprilExelixis, Inc. (NASDAQ:EXEL - Get Free Report) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 9,570,000 shares, a growth of 11.0% from the April 15th total of 8,620,000 shares. Currently, 3.4% of the company's shares are short sold. Based on an average daily trading volume, of 2,380,000 shares, the short-interest ratio is presently 4.0 days.May 17, 2024 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Shares Bought by BNP Paribas Financial MarketsBNP Paribas Financial Markets increased its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 88.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 450,097 shares of the biotechnology company'May 16, 2024 | insidertrades.comInsider Selling: Exelixis, Inc. (NASDAQ:EXEL) Director Sells 10,923 Shares of StockMay 15, 2024 | msn.comStephens & Co. Initiates Coverage of Exelixis (EXEL) with Equal-Weight RecommendationMay 14, 2024 | stocknews.com3 A-Rated Biotech Stocks for Long-Term InvestorsMay 14, 2024 | marketbeat.comExelixis (NASDAQ:EXEL) Now Covered by Analysts at StephensStephens began coverage on shares of Exelixis in a report on Tuesday. They issued an "equal weight" rating and a $23.00 price target on the stock.May 12, 2024 | marketbeat.comSeizert Capital Partners LLC Sells 43,339 Shares of Exelixis, Inc. (NASDAQ:EXEL)Seizert Capital Partners LLC lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 9.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 420,335 shares of the biotMay 12, 2024 | fool.comBillionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?May 11, 2024 | msn.comExelixis files patent suit against India’s Cipla over Cabometyx genericsMay 11, 2024 | marketbeat.comSwiss National Bank Decreases Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)Swiss National Bank lessened its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 12.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 564,700 shares of the biotechnology company's stock after selling 79,500 shMay 10, 2024 | marketwatch.comExelixis Files Patent Complaint Against Cipla's Cancer TreatmentMay 9, 2024 | marketbeat.comLSV Asset Management Sells 879,211 Shares of Exelixis, Inc. (NASDAQ:EXEL)LSV Asset Management trimmed its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 84.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 158,429 shares of the biotechnology company's stock after selMay 7, 2024 | businesswire.comExelixis to Webcast Fireside Chats as Part of Investor Conferences in MayMay 4, 2024 | marketbeat.comSummit Global Investments Purchases Shares of 38,458 Exelixis, Inc. (NASDAQ:EXEL)Summit Global Investments purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 38,458 shares of the biotechnology company's stock, valued at approximately $923May 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Exelixis Amid Solid Revenue and Strategic Growth InitiativesMay 3, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Exelixis (NASDAQ:EXEL)HC Wainwright reissued a "buy" rating and issued a $28.00 price objective on shares of Exelixis in a report on Friday.May 3, 2024 | marketbeat.comWilliam Blair Comments on Exelixis, Inc.'s Q3 2024 Earnings (NASDAQ:EXEL)Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Equities research analysts at William Blair decreased their Q3 2024 EPS estimates for Exelixis in a research report issued on Wednesday, May 1st. William Blair analyst A. Hsieh now expects that the biotechnology company will earn $0.27 per share for thMay 2, 2024 | markets.businessinsider.comHold Rating on Exelixis: Analyzing Q1 Revenue Shortfalls and Pipeline ProgressMay 2, 2024 | seekingalpha.comExelixis: With Patent Litigation Decision Due Soon, There Are OptionsMay 2, 2024 | finance.yahoo.comExelixis, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowMay 1, 2024 | finance.yahoo.comGiants of Cancer Care® Announces the 12th Annual Class of InducteesMay 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Inari Medical (NARI), Exelixis (EXEL) and Merit Medical Systems (MMSI)May 1, 2024 | finance.yahoo.comExelixis Inc (EXEL) Q1 2024 Earnings: Mixed Results Amidst Restructuring EffortsMay 1, 2024 | markets.businessinsider.comThe Analyst Verdict: Exelixis In The Eyes Of 5 ExpertsMay 1, 2024 | marketbeat.comExelixis (NASDAQ:EXEL) Given New $27.00 Price Target at TD CowenTD Cowen boosted their target price on shares of Exelixis from $25.00 to $27.00 and gave the company a "buy" rating in a research report on Wednesday.May 1, 2024 | marketbeat.comExelixis (NASDAQ:EXEL) Announces Earnings ResultsExelixis (NASDAQ:EXEL - Get Free Report) posted its quarterly earnings results on Tuesday. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.16). Exelixis had a return on equity of 8.57% and a net margin of 11.35%. The company had revenue of $425.23 million during the quarter, compared to analyst estimates of $461.04 million. During the same quarter in the prior year, the business earned $0.12 earnings per share. The business's revenue for the quarter was up 4.0% on a year-over-year basis.May 1, 2024 | marketbeat.comExelixis (NASDAQ:EXEL) Stock Rating Reaffirmed by William BlairWilliam Blair reissued an "outperform" rating on shares of Exelixis in a report on Wednesday.May 1, 2024 | marketbeat.comExelixis (NASDAQ:EXEL) Shares Gap Down on Disappointing EarningsExelixis (NASDAQ:EXEL) Shares Gap Down After Earnings MissMay 1, 2024 | msn.comExelixis down 7% as Q1 financial results disappointMay 1, 2024 | finance.yahoo.comExelixis Inc (EXEL) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 1, 2024 | finance.yahoo.comQ1 2024 Exelixis Inc Earnings CallMay 1, 2024 | marketbeat.comRussell Investments Group Ltd. Purchases 37,438 Shares of Exelixis, Inc. (NASDAQ:EXEL)Russell Investments Group Ltd. raised its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,513,591 shares of the biotechnology companMay 1, 2024 | fool.comExelixis (EXEL) Q1 2024 Earnings Call TranscriptApril 30, 2024 | finance.yahoo.comExelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address REPLAY AVAILABLE: $0.25 Cent Trades (Ad)Recently, I revealed how my new $0.25 Cent Trades works… If you didn’t see it, here’s the deal… As long as the $0.25 Cent Trades are set the day before some predetermined dates my team and I found… Well, that’s when the magic happens… Click now to see for yourself what $0.25 Cent Trades is all about EXEL Media Mentions By Week EXEL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EXEL News Sentiment▼0.940.87▲Average Medical News Sentiment EXEL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EXEL Articles This Week▼147▲EXEL Articles Average Week Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Charles River Laboratories International News National Research News Medpace News Precigen News Luna Innovations News Alnylam Pharmaceuticals News BioMarin Pharmaceutical News Neurocrine Biosciences News Incyte News United Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EXEL) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.